Potential impact of prior high-dose IL-2 on the outcomes of sunitinib (Su) treatment (tx) in patients (pts) with metastatic renal cell carcinoma (mRCC)
| العنوان: | Potential impact of prior high-dose IL-2 on the outcomes of sunitinib (Su) treatment (tx) in patients (pts) with metastatic renal cell carcinoma (mRCC) |
|---|---|
| المؤلفون: | David Sarid, Daniel Kejzman, Keren Rouvinov, Maya Gottfried, Mario A. Eisenberger, Avivit Peer, Raanan Berger, Victoria Neiman, Eli Rosenbaum, Victoria J. Sinibaldi, Avishay Sella, Wilmosh Mermershtain, Henry Hayat, Eliahu Gez, Hans J. Hammers, Michael A. Carducci |
| المصدر: | Journal of Clinical Oncology. 32:494-494 |
| بيانات النشر: | American Society of Clinical Oncology (ASCO), 2014. |
| سنة النشر: | 2014 |
| مصطلحات موضوعية: | Oncology, Cancer Research, medicine.medical_specialty, Potential impact, Proportional hazards model, Sunitinib, business.industry, medicine.medical_treatment, Cancer, Single Center, medicine.disease, Nephrectomy, Surgery, Renal cell carcinoma, Internal medicine, medicine, Progression-free survival, business, medicine.drug |
| الوصف: | 494 Background: Targeted txs are the tx of choice in most mRCC pts. However, HDIL2 which may produce durable responses in a small percentage of cases, is still an option in carefully selected pts. While the effect of prior HDIL2 on the outcome of targeted txs in mRCC pts is poorly defined, a recent single center report (Birkhäuser FD, Cancer J 2013) revealed an improved disease-specific survival in pts treated with prior HDIL2. We aimed to study the effect of prior HDIL2 tx on outcome of mRCC pts treated with sunitinib. Methods: Records from 302 mRCC pts treated with Su from 2004 to 2013 in 9 centers across 2 countries were retrospectively reviewed. We compared the response rate, progression free survival (PFS), and overall survival (OS), between post HDIL2 pts (n=27) and individually matched tx naïve pts (n=27). Progression free survival and overall survival were determined by Cox regression. Results: All pts had prior nephrectomy and clear cell histology. The groups were matched by age (median 61), gender (male 74%), Heng risk (favorable 37%, intermediate 59%, poor 4%), sunitinib induced hypertension (67%), sunitinib dose reduction/treatment interruption (41%), smoking status (active 7%), use of angiotensin system inhibitors (41%), the presence of more than one metastases site (96%), and pre-tx neutrophil to lymphocyte ratio (> 3 in 22%). Furthermore, they were balanced regarding the presence of lung (68%), liver (31%), and bone (43%) metastases, and the use of bisphosphonates (32%). In prior HDIL2 versus tx naïve pts, objective response was partial response/stable disease 89% (n=24) versus 74% (n=20), and progressive disease at first imaging evaluation within the first 3 months (mos) 11% (n=3) versus 26% (n=7) (p=0.29, OR 2.4). Median progression free survival was 21 versus 12 mos (HR 2.3, p=0.005), and median overall survival 25 versus 20 mos (HR 2.2, p=0.013). Conclusions: In metastatic renal cell carcinoma patients treated with sunitinib, prior high dose IL-2 therapy may improve the outcome. |
| تدمد: | 1527-7755 0732-183X |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_________::ec5e0e29db127a0af52c7ffd5be25f43 https://doi.org/10.1200/jco.2014.32.4_suppl.494 |
| رقم الأكسشن: | edsair.doi...........ec5e0e29db127a0af52c7ffd5be25f43 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15277755 0732183X |
|---|